Nasus Pharma (NSRX)
Develops powder-based nasal drugs for acute medical emergencies.
$3.77
At close−0.05 (−1.44%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 6 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 |
| Operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −3 | −6 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | 0 | 0 | 0 | 0 | 0 | −1 | −1 | −1 | −3 | −6 |
| Net income from continuing operations | 0 | 0 | 0 | 0 | 0 | −1 | −1 | −1 | −3 | −6 |
| Discontinued operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | 0 | 0 | 0 | 0 | 0 | −1 | −1 | −1 | −3 | −6 |
| EPS, basic | −$0.06 | −$0.06 | −$0.06 | −$0.05 | −$0.05 | −$0.08 | −$0.08 | −$0.15 | −$0.27 | −$0.54 |
| EPS, diluted | −$0.06 | −$0.07 | −$0.07 | −$0.05 | −$0.05 | −$0.08 | −$0.08 | −$0.15 | −$0.27 | −$0.54 |
| Weighted average shares, basic | 7 | 7 | 7 | 7 | 7 | 8 | 8 | 9 | 11 | 11 |
| Weighted average shares, diluted | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 9 | 11 | 11 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | 0 | −6 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 |
| EBIT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −3 | −6 |